Industry Newsbiotechneuromuscular diseasesdyne therapeuticsclinical pipeline
Dyne Therapeutics Draws Bullish Ratings, Gains Upside
5.0
Dyne Therapeutics is receiving bullish analyst coverage as of December 19, with 10 analysts reporting and 80% issuing Buy ratings. The consensus one-year price target is $38.40, implying roughly 93% upside, while Evercore ISI on December 15 reaffirmed a Buy with a $36 target implying about 81% potential gain. Dyne develops targeted neuromuscular therapeutics using its FORCE platform and maintains a clinical and preclinical pipeline.
Key Points
- 1Reports show 10 analysts cover DYN; 80% give Buy, one-year target $38.40.
- 2Analysts cite encouraging functionality, efficacy and safety metrics alongside a recent fundraising catalyst.
- 3Signals potential investor upside: analyst targets imply roughly 81–93% gains, but biotech risks persist.
Scoring Rationale
Analyst-backed price targets provide actionable investment signals, but news is a routine coverage update with limited market-moving novelty.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
